WallStSmart

Fox Corp Class B (FOX)vsGlaxoSmithKline PLC ADR (GSK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GlaxoSmithKline PLC ADR generates 98% more annual revenue ($32.78B vs $16.58B). GSK leads profitability with a 17.8% profit margin vs 11.4%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).

FOX

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.44

GSK

Strong Buy

66

out of 100

Grade: B-

Growth: 4.7Profit: 9.0Value: 7.3Quality: 4.0
Piotroski: 5/9Altman Z: 1.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FOXUndervalued (+31.8%)

Margin of Safety

+31.8%

Fair Value

$81.27

Current Price

$56.60

$24.67 discount

UndervaluedFair: $81.27Overvalued
GSKFair Value (-3.1%)

Margin of Safety

-3.1%

Fair Value

$56.71

Current Price

$50.41

$6.30 premium

UndervaluedFair: $56.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FOX2 strengths · Avg: 8.0/10
P/E RatioValuation
13.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

GSK5 strengths · Avg: 9.4/10
PEG RatioValuation
0.5010/10

Growing faster than its price suggests

Return on EquityProfitability
40.9%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
36.3%10/10

Strong operational efficiency at 36.3%

Market CapQuality
$101.38B9/10

Large-cap with strong market position

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Areas to Watch

FOX4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PEG RatioValuation
12.872/10

Expensive relative to growth rate

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Free Cash FlowQuality
$-773.00M2/10

Negative free cash flow — burning cash

GSK3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

Debt/EquityHealth
1.103/10

Elevated debt levels

Altman Z-ScoreHealth
1.262/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : FOX

The strongest argument for FOX centers on P/E Ratio, Price/Book.

Bull Case : GSK

The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.

Bear Case : FOX

The primary concerns for FOX are Revenue Growth, PEG Ratio, EPS Growth.

Bear Case : GSK

The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.

Key Dynamics to Monitor

FOX carries more volatility with a beta of 0.53 — expect wider price swings.

FOX is growing revenue faster at 2.0% — sustainability is the question.

GSK generates stronger free cash flow (698M), providing more financial flexibility.

Monitor ENTERTAINMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GSK scores higher overall (66/100 vs 51/100), backed by strong 17.8% margins. FOX offers better value entry with a 31.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fox Corp Class B

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Fox Corporation is an American mass media company headquartered in New York City.

GlaxoSmithKline PLC ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Want to dig deeper into these stocks?